Interferon Beta-1a (Biogen, Inc.)

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year – NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. "During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic," said Erik Lundgren, Chief Executive Officer of Immunic. "As we prepare for the next stage of Immunic's growth, we have continued to strengthen our board and team with world-class multiple sclerosis (MS) experts whose extensive development, medical, regulatory and commercialization expertise will be instrumental as we execute on our clinical strategy and prepare for the potential regulatory filings and commercialization of vidofludimus calcium (IMU-838). Following the successful closing of our oversubscribed private placement financing earlier this year, we are well capitalized to execute on our key strategic priorities. We believe the milestones ahead position Immunic for a significant near-term value inflection for vidofludimus calcium in relapsing MS, while continuing to unlock the substantial long-term opportunity across the broader progressive MS patient population." Jason Tardio, President and Chief Operating Officer of Immunic, commented, "We remain highly encouraged by the consistent and differentiated profile of vidofludimus calcium, supported by additional data from our Phase 2 CALLIPER trial in progressive MS presented at this year's CMSC Annual Meeting, including favorable safety, tolerability, patient-reported, and exploratory efficacy data. Taken together, these findings reinforce our confidence in the potential of vidofludimus calcium to offer a differentiated benefit/risk profile through its novel dual mechanism of action, combining Nurr1 activation with selective DHODH inhibition. We believe this approach has the potential to deliver meaningful efficacy while maintaining the favorable safety and tolerability profile observed to date, positioning vidofludimus calcium as a potentially important new oral treatment option for people living with MS." "Our Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS remain on track to report top-line data by the end of 2026," added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. "With regulatory alignment and precedent surrounding the time to first relapse primary endpoint, the path to regulatory submission upon positive trial results is clear. In parallel, we are preparing to initiate our Phase 3 progressive MS trial later this year, reinforcing our commitment to evaluating the potential of vidofludimus calcium for anyone living with MS." Second Quarter 2026 and Subsequent Highlights Ongoing Phase 3 ENSURE Relapsing MS Program: Continued to execute the twin Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS. Preparation of Phase 3 Progressive MS Program: Continued preparations for a confirmatory Phase 3 program in progressive MS, building on the Phase 2 CALLIPER trial data. Additional Phase 2 CALLIPER Data Presented at CMSC Annual Meeting: Presented one late-breaking and two additional posters of new data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The new analyses, which included a novel unified confirmed disability change (CDC) endpoint, up to 120 weeks of patient-reported outcomes, and safety and tolerability data, further reinforced the favorable profile of vidofludimus calcium and its potential to address underlying drivers of disability progression in progressive MS. Expansions in Management and Board of Directors: Appointment of Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment having begun on June 1, 2026. Mr. Lundgren is a biopharmaceutical executive with nearly two decades of commercial leadership experience, including senior roles at Genentech and Roche supporting the launch of Ocrevus® for relapsing and primary progressive MS. On July 5, 2026, Mr. Lundgren was also appointed to serve as a Director of the Board. Appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026. Dr. Panzara brings over 25 years of global neurology experience and proven leadership in advancing transformational therapies through development and regulatory approval processes. Dr. Panzara oversaw the global regulatory approvals of the MS drugs Lemtrada® and Aubagio® during his tenure at Sanofi Genzyme. During his time at Biogen, he served as global clinical lead for the development of Tysabri® and managed the late-stage MS portfolio. In addition, Michael W. Bonney has been appointed as Chair of the Board of Directors, effective May 16, 2026. Mr. Bonney is a seasoned biopharmaceutical executive with more than three decades of leadership experience, including senior commercial roles at Biogen tied to the launch and growth of Avonex® for relapsing MS and CEO experience at Cubist Pharmaceuticals. Simona Skerjanec, M.Pharm, M.B.A., transitioned from Interim Chairperson to continue serving as a Board member. Appointment of Elena Ridloff to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than 20 years of leadership experience in finance, corporate development, investor relations, and capital markets across the biopharmaceutical industry. She currently serves as Chief Financial Officer at Sionna Therapeutics. Anticipated Clinical Milestones Vidofludimus Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials remains on track and is expected to be available by the end of 2026. If positive, Immunic plans to submit a New Drug Application (NDA) in the United States in mid-2027, with a targeted potential regulatory approval date in 2028. Vidofludimus Calcium in Progressive MS: The planned initiation of a Phase 3 program in progressive MS remains on track for later this year. IMU-381: The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune diseases, continues to be in preclinical testing with lead candidate identification ongoing. Financial and Operating Results Total Operating Expenses for the three and six months ended June 30, 2026 were $35.3 million and $68.6 million, respectively. Included in these results are $7.2 million and $11.7 million, respectively, of non-cash charges, primarily related to stock compensation expense. Research and Development (R&D) Expenses were $25.9 million for the three months ended June 30, 2026, as compared to $21.3 million for the three months ended June 30, 2025. The $4.6 million increase reflects (i) a $4.4 million increase in personnel expenses, $3.2 million of which was related to non-cash stock compensation, (ii) a $1.6 million increase due to drug-drug interaction studies in support of a potential NDA filing, (iii) a $1.1 million increase related to costs across numerous categories, partially offset by (iv) a $2.0 million decrease related to the CALLIPER clinical trial and (v) a $0.5 million decrease related to the ENSURE clinical trials. For the six months ended June 30, 2026, R&D expenses were $51.6 million, as compared to $42.9 million for the six months ended June 30, 2025. The $8.7 million increase reflects (i) a $5.4 million increase in personnel expenses, $3.8 million of which was related to non-cash stock compensation, (ii) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing, (iii) a $3.1 million increase for vidofludimus calcium drug supply and (iv) a $1.3 million increase related to costs across numerous categories, partially offset by (v) a $2.8 million decrease related to the CALLIPER clinical trial and (vi) a $2.2 million decrease related to the ENSURE clinical trials. General and Administrative (G&A) Expenses were $9.4 million for the three months ended June 30, 2026, as compared to $5.7 million for the same period ended June 30, 2025. The $3.7 million increase was due to (i) a $2.1 million increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.7 million increase in legal and consultancy expenses, (iii) a $0.4 million increase in pre-commercial marketing expenses, and (iv) a $0.5 million increase in related costs across numerous categories. For the six months ended June 30, 2026, G&A expenses were $17.0 million, as compared to $11.0 million for the same period ended June 30, 2025. The $6.0 million increase was due to (i) a $4.2 million increase related to personnel expenses, of which $3.6 million was related to non-cash stock compensation, (ii) a $1.0 million increase in legal and consultancy expenses, (iii) a $0.6 million increase in pre-commercial marketing expenses, and (iv) a $0.2 million increase in related costs across numerous categories. Interest Income was $1.3 million for the three months ended June 30, 2026, as compared to $0.3 million for the three months ended June 30, 2025. The $1.0 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement. For the six months ended June 30, 2026, interest income was $2.0 million, as compared to $0.4 million for the same period ended June 30, 2025. The $1.6 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement. Other Income (Expense) was ($0.06) million for the three months ended June 30, 2026, as compared to $0.02 million for the same period ended June 30, 2025. For the six months ended June 30, 2026, Other Income (Expense) was ($0.2 million), as compared to $1.2 million for the same period ended June 30, 2025. The $1.4 million decrease was primarily attributable to (i) a $1.0 million grant income of the German Federal Ministry of Finance recognized in the first quarter 2025 and no grant income in 2026 and (ii) a $0.4 million decrease across various categories. Net Loss for the three months ended June 30, 2026, was approximately $34.1 million, or $0.80 per basic and diluted share, based on 42,513,839 weighted-average common shares outstanding, compared to a net loss of approximately $26.8 million, or $2.03 per basic and diluted share, based on 13,217,520 weighted-average common shares outstanding for the same period ended June 30, 2025. Net loss for the six months ended June 30, 2026, was approximately $66.7 million, or $1.83 per basic and diluted share, based on 36,359,274 weighted average common shares outstanding, compared to a net loss of approximately $52.3 million or $4.48 per basic and diluted share, based on 11,684,499 weighted average common shares outstanding for the same period ended June 30, 2025. Cash and Cash Equivalents as of June 30, 2026 were $155.1 million. With these funds, Immunic expects to be able to fund its operations into late 2027. About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: . Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact LifeSci Advisors Joyce Allaire [email protected] US Media Contact Real Chemistry [email protected] Financials SOURCE Immunic, Inc. 21% more press release views with Request a Demo

🧩 导读：卫材株式会社（Eisai Co., Ltd.）作为日本头部制药企业，在 \\ 自身免疫性疾病（Autoimmune Disease, AD）赛道，整体呈现"合作商业化为主、自研早期探索为辅"\\ 的布局特征：成熟产品以引进合作的方式覆盖日本本土市场，自研管线仅聚焦少量差异化新颖靶点，整体处于临床早中期阶段。 🔬一、自免领域商业化产品 卫材在自免领域的已上市产品均为与外部企业合作开发 / 商业化的品种，主要覆盖日本市场，涵盖风湿免疫、消化免疫、皮肤免疫等细分方向。 通用名 商品名 作用机制 日本获批自免适应症 合作方 合作模式 备注 阿达木单抗（Adalimumab） 修美乐 ®（Humira®） 全人源抗TNF-α单克隆抗体 类风湿关节炎（Rheumatoid Arthritis, RA）、斑块型银屑病、银屑病关节炎、脓疱型银屑病、强直性脊柱炎、多关节型幼年特发性关节炎、克罗恩病、溃疡性结肠炎、化脓性汗腺炎、坏疽性脓皮病、肠白塞病、非感染性葡萄膜炎 艾伯维（AbbVie） 日本市场共同推广 艾伯维持有上市许可，卫材负责日本市场部分医疗机构的推广与学术活动，是日本自免领域覆盖适应症最广的生物制剂之一 非戈替尼（Filgotinib） Jyseleca® 口服JAK1优先抑制剂 对常规治疗应答不足的类风湿关节炎（含结构性关节损伤预防）；中度至重度活动性溃疡性结肠炎 吉利德科学（Gilead Sciences） 日本市场分销 + 共同商售 吉利德日本持有上市许可并负责生产供应，卫材负责日本市场产品分销与商业化推广；类风湿关节炎适应症 2020 年获批，溃疡性结肠炎适应症 2022 年获批 \\ 甲氨蝶呤（Methotrexate）\\ 皮下注射剂 Metoject® 叶酸拮抗剂，免疫抑制与抗炎 类风湿关节炎 德国medac 日本市场独家分销 2022 年 9 月预充注射器剂型在日本获批，2024 年新增自动注射笔剂型；日本 medac 持有上市许可，卫材负责日本市场产品分销，为类风湿关节炎一线基础治疗药物 注：卫材曾于 2018-2023 年与渤健（Biogen）在日本共同推广富马酸二甲酯（Dimethyl Fumarate, DMF）（TECFIDERA®）、那他珠单抗（Natalizumab）（TYSABRI®）、干扰素 β-1a（Interferon beta-1a）（AVONEX®）三款 \\ 多发性硬化（Multiple Sclerosis, MS）\\ 治疗药物，该合作协议已于 2023 年 3 月 31 日终止，目前相关产品由渤健日本全权负责商业化运营。 🔬二、自免领域核心产品 核心产品为卫材自免业务中商业价值最高、战略定位最核心的品种，覆盖成熟商业化品种与自研重点管线两大类别。 产品 / 管线名称 类型 作用机制 适应症 阶段 核心定位 阿达木单抗（修美乐 ®） 合作商业化产品 抗TNF-α单抗 多系统自身免疫疾病 已上市 日本自免市场核心商业化品种，覆盖适应症广、患者基数大，是公司自免业务收入的核心支撑 非戈替尼（Jyseleca®） 合作商业化产品 口服JAK1抑制剂 类风湿关节炎、溃疡性结肠炎 已上市 口服自免药物的核心布局，覆盖风湿与消化两大自免赛道，与生物制剂形成治疗路径互补 E6742 自研在研管线 口服TLR7/8选择性拮抗剂 系统性红斑狼疮（Systemic Lupus Erythematosus, SLE） 临床 II 期 自研自免管线的核心战略品种，聚焦系统性红斑狼疮未满足临床需求，靶点机制具有差异化 🔬三、自免领域在研临床管线 卫材自研自免管线整体处于临床早中期阶段，聚焦新颖免疫通路，部分早期项目已对外授权合作开发。 药物代号 作用机制 适应症 开发地区 最新公开状态 备注 E6742 口服TLR7/8选择性拮抗剂 系统性红斑狼疮（SLE） 美国、日本 临床 II 期进行中 卫材自研核心品种，通过抑制TLR7/8通路减少I 型干扰素（Type I Interferon, IFN-I）与炎症因子生成；I 期及 12 周 I/II 期研究已完成，可显著下调患者干扰素基因特征（Interferon Gene Signature, IGS），显示出初步的疾病活动度改善趋势；目前正在开展 24 周 II 期确证性研究 E6011 抗 \\Fractalkine（CX3CL1）\\ 人源化单克隆抗体 类风湿关节炎、克罗恩病、原发性胆汁性胆管炎 日本 临床 II 期完成，后续进展未公开 全球首个抗Fractalkine单抗，通过抑制免疫细胞迁移发挥抗炎作用；类风湿关节炎 II 期：12 周ACR20主要终点未达统计学显著，24 周高剂量组ACR20较安慰剂达到统计学差异；克罗恩病早期 II 期因入组缓慢提前终止，未达预设疗效终点；消化领域适应症由EA Pharma合作开发 临床 II 期 已对外授权项目 药物代号 作用机制 适应症 授权方 授权时阶段 备注 E6005（Lotamilast） 外用选择性PDE4抑制剂 特应性皮炎（Atopic Dermatitis, AD） Roivant Sciences 临床 II 期 2015 年卫材将全球开发与商业化权益独家授权给 Roivant，保留里程碑付款与销售分成；该药物系统暴露量低，可同时改善皮肤炎症与瘙痒；授权后无显著后期临床进展公开披露 🔬四、最有潜力的自免临床管线 综合靶点创新性、适应症未满足需求、临床数据表现，卫材自研管线中E6742为当前最具开发潜力的品种。 药物代号 作用机制 适应症 开发阶段 潜力依据 E6742 口服TLR7/8选择性拮抗剂 系统性红斑狼疮（SLE） 临床 II 期 1. 靶点机制差异化：TLR7/8是 SLE 发病的核心上游通路，参与I 型干扰素过度激活与自身抗体生成，该靶点口服抑制剂全球范围内处于早期开发阶段，竞争格局相对缓和；                  2. 临床前与早期临床数据支撑：在 SLE 小鼠模型中可显著降低自身抗体水平、改善肾脏病理；I/II 期临床可显著下调患者干扰素基因特征（IGS），同时显示出初步的疾病活动度改善趋势，安全性与耐受性良好；                  3. 剂型具备依从性优势：口服给药相较于现有生物制剂可提升患者长期治疗依从性，适配 SLE 慢性长期管理的临床需求 🔬五、总结 整体来看，卫材在自身免疫性疾病领域布局呈现清晰的分层特征： 1.商业化端依托与艾伯维、吉利德、medac等企业的合作，在日本市场覆盖了风湿免疫、消化免疫、皮肤免疫等主流自免适应症，形成了成熟的产品矩阵，是当前自免业务的核心收入来源； 2.研发端仅布局少量早中期管线，聚焦TLR7/8、Fractalkine（CX3CL1）等差异化靶点，走小而精的创新路线，其中E6742是当前自研管线中最具代表性的品种； 3.公司自免管线整体阶段偏早，自研项目后续临床推进、适应症拓展与商业化落地仍存在不确定性，其长期价值有待后续临床数据的持续验证。 📌数据来源 1.卫材株式会社官方研发管线与合作公告（2023-2026 年公开披露） 2.卫材（中国）药业有限公司官方新闻稿 3.公开临床研究文献（PubMed、PMC 平台收录） 4.企业合作授权公开公告（艾伯维、吉利德、medac、Roivant 等） 跨国药企默沙东 MSD在自免领域的商业化+在研临床管线布局 日本田边制药（Tanabe Pharma ）在自身免疫疾病领域的商业化和临床管线布局 自免领域Top14跨国药企适应症布局和研发汇总 跨国药企大冢制药（Otsuka ）在自身免疫疾病领域的商业化+精准临床管线布局 日本头部跨国制药企业|协和麒麟（Kyowa Kirin）在自免领域的管线布局 全球12+头部跨国药企在自身免疫性疾病领域的布局 日本跨国药企第一三共（Daiichi Sankyo）在自身免疫疾病领域的布局 跨国生物公司|渤健（Biogen）在自身免疫疾病领域的商业化产品+临床在研管线+临床管线竞争梳理 制药巨头吉利德科学（Gilead）自身免疫与炎症领域管线 跨国药企安进（Amgen）自身免疫疾病领域管线 百时美施贵宝（BMS）自身免疫疾病领域管线 全球制药企业优时比（UCB）自免领域管线 跨国药企|武田制药Takeda|在自身免疫疾病领域的布局（商业化和临床管线） 葛兰素史克（GSK）在自免和炎症领域的布局|3款重磅药 + 8 条临床管线！ 跨国药企|辉瑞（Pfizer）在自身免疫疾病领域的商业化产品与临床研发管线 跨国药企|阿斯利康自身免疫疾病领域商业化产品和临床管线 跨国药企|罗氏（Roche）在自免领域的商业化产品及临床管线 自免领域|通用型CAR-T产品新进展|全球首款靶向CD19与CD38双靶点的通用型CAR-T：FT839 美万亿美元市值制药巨头|礼来（Eli Lilly & Co.）|自身免疫疾病领域商业化产品和临床管线 瑞士全球性制药公司|诺华Novartis自身免疫疾病领域商业化产品和临床管线 勃林格殷格翰|那米司特（Nerandomilast）治疗特发性肺纤维化（IPF）与进展性肺纤维化（PPF）的两项全球多中心 III 期临床试验回溯总结 跨国药企|艾伯维（AbbVie）自身免疫疾病领域|商业化产品和临床管线 跨国制药巨头|赛诺菲（Sanofi）|自身免疫与炎症领域：商业化产品和临床管线 迎接七月|自身免疫疾病领域IL-17A靶点临近上市资产重磅 BD 合作 跨国制药巨头Johnson & Johnson Pharmaceutical（强生制药）自身免疫疾病领域核心产品与临床管线 2026年6月全球自身免疫性疾病创新药研发进展 跨国药企全球 Top15|在自身免疫疾病领域的商业布局与重点研发管线 中国本土创新药企（不含跨国药企）在自免领域的布局总结 CD38单抗达雷妥尤单-治疗系统性红斑狼疮单臂Ⅱ期临床试验完整总结 再闯港股IPO！岸迈生物凭差异化TCE技术，改写自免创新竞争格局 突破SLE治疗瓶颈！惠和生物CC312解锁自免TCE一年长效免疫重置新范式 Kali Therapeutics, Inc：可控型T细胞衔接技术，重塑自身免疫疾病精准治疗赛道 肠道菌群：自身免疫病的关键诱因 【版权说明】：本公众号所有文章仅为医药行业信息梳理与行业动态分享，且已注明创作信息来源。本公众号欢迎分享朋友圈或大群，但谢绝媒体或机构未经授权以任何形式转载至其他平台。 【免责声明】：文中观点不代表自免药研社立场，亦不代表自免药研社支持或反对文中观点。仅作信息交流之目的，不构成任何诊疗建议、用药指导或投资决策参考。药物研发具有不确定性，实际研发进度与结果可能与预期存在差异，具体请以企业官方与监管机构最新披露为准。